Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5429111 | 0.80 | LMNA (0.36) | CYP1A2ALDH1A1HSD17B10MAPTKMT2A | |
| SCHEMBL5429108 | 0.60 | LRRK2 (0.43) | CYP1A2ALDH1A1HSD17B10MAPTUSP2 | |
| SCHEMBL5217571 | 0.58 | CTSD (0.51) | CYP1A2ALDH1A1HSD17B10KMT2AMEN1 | |
| SCHEMBL7231634 | 0.57 | HCAR3 (0.49) | CYP1A2ALDH1A1HSD17B10USP2 | |
| SCHEMBL5871771 | 0.57 | NAMPT (0.47) | — | |
| SCHEMBL5217461 | 0.57 | ALDH1A1 (0.47) | CYP1A2ALDH1A1HSD17B10KMT2AMEN1 | |
| SCHEMBL21842818 | 0.57 | GPR84 (0.41) | ALDH1A1MAPT | |
| SCHEMBL5217257 | 0.57 | ALDH1A1 (0.50) | CYP1A2ALDH1A1HSD17B10KMT2AMEN1 | |
| SCHEMBL9683080 | 0.56 | PIK3CD (0.42) | ALDH1A1KMT2A | |
| SCHEMBL9684772 | 0.56 | PIK3CD (0.42) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | CYP1A2 2757/4885ALDH1A1 3102/4885HSD17B10 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.